MACK News and Press, Merrimack Pharmaceuticals Inc. From 10/11/19

Small-cap stocks have underperformed large-cap stocks, and recent manufacturing and services industry data increases concerns that profits could stagnate. The risk of decelerating economic activity to small-cap stocks shouldn't be ignored, but that doesn't mean there aren't sectors, industries...

Overview Merrimack Pharmaceuticals, Inc. ([[MACK]]) (“MACK” or the “Company”) is a clinical-stage biopharmaceutical company focused on oncology drugs. Recently, through the help of some engaged shareholders, management shuttered its development operations by selli...

LAKEWAY, Texas , Sept. 24, 2019 /PRNewswire/ -- JFL Capital Management, LLC (together with its affiliates, "JFL Capital"), the largest stockholder of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") (NASDAQ: MACK), with ownership of approximately 9.4% of the Company's o...

Company Enters into Cooperation Agreement with Newtyn Management and Western Standard Independent Directors Noah Levy of Newtyn and Eric Andersen of Western Standard to Be Added to Merrimack Board, Effective Immediately Newtyn and Western Have Agreed to Vote for Merrimack S...

Dividend Amount is $1.496675 per Outstanding Share of Merrimack Common Stock and Will be Paid Today, as Previously Announced Company Provides Update on NOL Carryforwards; No Impairment as of July 24, 2019 Merrimack Pharmaceuticals (Nasdaq: MACK) (the “Company” or...

Company’s Board has Taken Crucial Actions to Maximize Shareholder Value and Preserve More than $500 Million in Potential Future Milestone Payments Merrimack’s Current Plan Follows Comprehensive Strategic Review Conducted with Leading Healthcare Financial Advisory Firm...

LAKEWAY, Texas , Aug. 22, 2019 /PRNewswire/ -- JFL Capital Management, LLC, together with its affiliates and the other participants in its solicitation, the largest stockholder of Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") (NASDAQ: MACK), with ownership of approximatel...

Merrimack Pharmaceuticals (Nasdaq: MACK) (the “Company” or “Merrimack”) announced today it is rescheduling its 2019 Annual Meeting of Shareholders (the “2019 Annual Meeting”) for October 17, 2019. As a result, the record date for the 2019 Annual Meeti...

CAMBRIDGE, Mass. , July 25, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $20 million on the Company's common stock. The special dividend is payable on Septem...

Merrimack Pharmaceuticals (NASDAQ: MACK ) is 2.6% lower in postmarket trading after the company says it wrapped a strategic review by deciding not to move forward with a sale . More news on: Merrimack Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Merger & acquis...